Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. Vaxil Bio Ltd.
  6. News
  7. Summary
    VXL   CA92243L1076


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Vaxil Bio : Announces CEO Resignation

05/05/2021 | 05:00pm EDT

Not for distribution by US newswire or in United States

NESS-ZIONA, Israel, May 05, 2021 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, today announces that Mr. David Goren has provided notice that he will be resigning as the Company's chief executive officer (“CEO”) to pursue other opportunities. The resignation will take effect on August 1, 2021 (the “Effective Date”). Mr. Goren has agreed that until the Effective Date, he will, in addition to continuing to fulfill his responsibilities as CEO, assist the Company's board of directors ("Board") in their search for a new CEO, which has already commenced.

The Board wishes to thank Mr. Goren for his contributions to the Company over the past two and a half years, and wishes him success in his future endeavors.

Mr. Goren remains a director of the Company.


The company posts periodic updates through videos from the official company’s YouTube channel https://www.youtube.com/channel/UC0M029aN8g6beW09Drgt0dQ

Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin™ successfully completed a Phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA and EMA. The company aims to continue to develop ImMucin™, a COVID-19 and a tuberculosis vaccine / treatment that has demonstrated promising preliminary results with further preclinical evaluation planned. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.

Vaxil exploits the unique properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens. These signal peptide domains are identified by VaxHit™, Vaxil’s proprietary bioinformatic approach. These signal peptides induce a robust T- and B-cell response across wide and varied HLA subtypes, while acting as true, universal neoantigens. The peptide platform targets these cells by “educating” or specifically activating the immune system to recognize and attack the affected cells. In addition, Vaxil’s mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer: The Company cautions that COVID-19 Vaccine Development is still under early stage research and development and is not making any express or implied claims that it has the ability to eliminate the COVID-19 virus at this time. The TSX Venture Exchange Inc. has in no way passed upon the merits of the Company and has neither approved nor disapproved the contents of this press release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the availability of funds, the results of financing efforts, the results of exploration activities -- that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States or elsewhere. These securities have not been, and will not be, registered in the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.

For further information please visit http://vaxil-bio.com/ or contact:
North Equities, info@northequities.com
David Goren, CEO -- info@vaxil-bio.com, +972 (52) 720-6000
Company Youtube channel

Primary Logo

Source: Vaxil Bio Ltd.

2021 GlobeNewswire, Inc., source Press Releases - Canada

All news about VAXIL BIO LTD.
08/30Vaxil Bio Ltd. Reports Earnings Results for the Second Quarter Ended June 30,..
08/04VAXIL BIO : Names Avnir as Interim Chief Executive as Goren Departs
08/04Vaxil Bio Ltd. Appoints Yuval Avnir as Interim Chief Executive Officer
08/04VAXIL BIO : Announces Changes to Senior Management and Provides Updates on Curre..
08/04Vaxil Bio Ltd. Announces Executive Changes
05/31Vaxil Bio Ltd. Reports Earnings Results for the First Quarter Ended March 31,..
05/31UPDATE : Vaxil Down Near 5% as Provides Research and Development Update
05/31VAXIL BIO : Provides Research and Development Update
05/05VAXIL BIO : Announces CEO Resignation
05/05David Goren Resigns as Chief Executive Officer of Vaxil Bio Ltd
More news
Sales 2020 - - -
Net income 2020 -1,36 M -1,06 M -1,06 M
Net cash 2020 1,50 M 1,17 M 1,17 M
P/E ratio 2020 -22,5x
Yield 2020 -
Capitalization 9,56 M 7,50 M 7,48 M
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees -
Free-Float 91,5%
Duration : Period :
Vaxil Bio Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VAXIL BIO LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Managers and Directors
Yuval Avnir Chief Executive Officer
Gadi Levin Chairman & Chief Financial Officer
Terry F. Plasse Chief Medical Officer
Ari S. Kellen Independent Director
Shawn Langer Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VAXIL BIO LTD.-76.67%8
MODERNA, INC.311.65%173 588
LONZA GROUP AG32.35%60 074
CELLTRION, INC.-23.26%31 904
SEAGEN INC.-10.81%28 420